^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | AiRuiKa (camrelizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC
Excerpt:
...Subjects with sensitizing EGFR mutation positive or ALK rearrangement positive, must have experienced disease recurrence or progression during or after one prior tyrosine kinase inhibitor regimen, who also have PD-L1 expression in tumor ≥ 50%, are eligible....
Trial ID:
Source:
Title:
An exploratory clinical study of camrelizumab combined with chemotherapy in adjuvant treatment of stage IIA-IIIA non-small cell lung cancer
Excerpt:
...Disease-free survival (DFS) rate - Disease-free survival (DFS) rate; Disease free survival - Disease free survival; Overall survival - Overall survival; PD-L1 expression and curative effect - PD-L1 expression and curative effect...
Trial ID:
More C2 evidence
Source:
Title:
An exploratory clinical study of camrelizumab combined with platinum-containing chemotherapy for neoadjuvant therapy in patients with non-small cell lung cancer
Excerpt:
...Major pathological response rate - Major pathological response rate; pathologic complete response - pathologic complete response; disease free survival - disease free survival; objective remission rate - objective remission rate; Relationship between PD-L1 expression and efficacy - Relationship between PD-L1 expression and efficacy...
Trial ID:
Less C2 evidence
Source:
Title:
Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study
Published date:
10/20/2021
Excerpt:
Median progression-free survival was 3.2 months (95% CI 2.0–3.4), and patients with positive PD-L1 TPS had longer progression-free survival. Median overall survival was 14.8 months (95% CI 10.2–18.7)….Camrelizumab showed improved efficacy compared with historical data of the second-line chemotherapy in pre-treated advanced/metastatic NSCLC. Patients with positive PD-L1 expression derived greater benefit from camrelizumab.
DOI:
https://doi.org/10.1007/s00262-021-03091-3
Trial ID:
Source:
Title:
P78.03 Camrelizumab Umbrella Trial Based on PD-L1 Expression: OS and PFS2 in Pre-Treated Advanced NSCLC
Published date:
01/12/2021
Excerpt:
...4 cohorts according to PD-L1 tumor proportion score (TPS) to receive camrelizumab at 200 mg IV Q2W…median follow-up was 22.9 months (95% CI 21.7–24.2). Median OS and PFS was 14.8 months (95% CI 10.3–18.8) and 3.2 months (95% CI 2.0–3.4), respectively. Third-line therapy and beyond was received by 65 (44.5%) patients. PFS2 was 10.0 months (95% CI 8.2–12.4)...Patients with positive PD-L1 expression derived greater benefit from camrelizumab...Table 1
Source:
Title:
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
Published date:
12/18/2020
Excerpt:
The two primary endpoints were progression-free survival per blinded independent central review, in all patients and in patients who were PD-L1 positive….Progression-free survival in this interim analysis was significantly prolonged with camrelizumab plus chemotherapy than with chemotherapy alone (median 11·3 months [95% CI 9·6–15·4] vs 8·3 months [6·0–9·7]; hazard ratio 0·60 [0·45–0·79]; one-sided p=0·0001).
Secondary therapy:
carboplatin + pemetrexed RTD
DOI:
10.1016/S2213-2600(20)30365-9
Trial ID:
